Patrick D. Kirwin - 03 Feb 2026 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role: Director
Signature: /s/ Max A. Milbury, Attorney in Fact for Patrick Kirwin
Issuer symbol: PMN
Transactions as of: 03 Feb 2026
Net transactions value: +$36,996
Form type: 4
Filing time: 05 Feb 2026, 20:36:47 UTC
Previous filing: 16 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kirwin Patrick D.	Director	C/O PROMIS NEUROSCIENCES INC., 1920 YONGE STREET, SUITE 200, TORONTO, ONTARIO, CANADA	/s/ Max A. Milbury, Attorney in Fact for Patrick Kirwin	05 Feb 2026	0001927062

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PMN	Common Shares	Award	$36,996	+3,050	+146%	$12.13	5,135	03 Feb 2026	Direct	F1, F2
holding	PMN	Common Shares						1,653	03 Feb 2026	By Patrick D. Kirwin Professional Corp	F2
holding	PMN	Common Shares						305	03 Feb 2026	By his spouse	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PMN	Warrants to purchase Common Shares	Award		+3,050			3,050	03 Feb 2026	Common Shares	3,050	$14.40	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 3,050 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 3,050 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
F2	Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025.
F3	The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.